首頁 > 市場調查報告書 > 醫療設備

醫學影像診斷

市場調查報告書

商品編碼

1410088

2023年至2028年臨床試驗影像市場預測

Clinical Trial Imaging Market - Forecasts from 2023 to 2028

出版日期: 2023年12月12日 | 出版商:

Knowledge Sourcing Intelligence | 英文 144 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

全球臨床試驗影像市場預計在預測期內複合年成長率為 5.84%。

影像檢查使醫療專業人員能夠看到人體內發生的情況。這些測試將身體暴露於各種能源來源下，包括 X光、聲波、放射性粒子和磁場。增加對研究計劃的投資，為癌症和慢性腎臟病等長期疾病開發創新的醫療解決方案，是臨床試驗成像市場的主要成長要素。此外，由於這種疾病的高發病率和醫療保健成本的上升，對增強治療解決方案的需求以及生物技術公司的崛起預計將進一步推動臨床試驗成像市場。

生技公司增加

越來越多專注於臨床試驗成像研究的生物技術公司預計將在未來幾年推動臨床試驗成像市場的發展。例如，根據印度國家投資促進和便利化管理局的數據，2022年印度生物技術產業價值超過801.2億美元，較2021年成長14%。此外，2022年印度生技研發領域投資約10億美元。根據 AusBiotech Snapshot 2022，澳洲生物技術產業 2022 年較 2019 年成長 43%。此外，領先的生物技術公司和新興企業（例如 BioTelemetry、WCG Clinical、CRISPR Therapeutics 和 10x Genomics）的存在進一步推動了臨床試驗成像市場的發展。

癌症患者增加

影像檢查可用於分析癌症，因為癌症不僅獲得生物學能力，而且常常表現出各種結構、生理和分子變化。因此，癌症病例的增加預計將擴大臨床試驗影像市場。例如，據世界衛生組織稱，2020 年，六分之一的死亡者（即約 1000 萬人）死於癌症，使其成為全球主要死亡原因。據估計，低收入和中等收入國家 30% 的癌症病例是由人類乳突病毒 (HPV) 和肝炎等致癌感染疾病引起的。對癌症治療方法的探索仍在繼續，新的分子標靶藥物有望比標準化療藥物活性更高、毒性更小，從而帶來更個體化的治療。管理範式正在朝著越來越個體化的護理方向轉變。

慢性病負擔增加

慢性病是一種長期疾病，使全球無數人衰弱，因此臨床試驗影像對於早期疾病檢測和早期治療以確保及時介入至關重要。糖尿病、腎臟疾病和心血管疾病等慢性疾病的增加預計將推動臨床試驗影像市場的發展。例如，在美國，超過七分之一的成年人（即約 3700 萬人）患有慢性腎臟病(CKD)（根據 NIDDK）。全球死亡的主要原因是心血管疾病（CVD）。預計 2019 年，CVD 將佔全球死亡人數的 32%，死亡人數為 1,790 萬人。根據世界衛生組織的數據，心臟病和中風佔這些死亡人數的 85%。

該領域研究計劃的增加

涉及影像臨床試驗的研究計劃的增加也是臨床試驗影像市場的主要成長要素。例如，美國國家醫學圖書館報告稱，截至2022年4月，美國50個州和220個外國有410,319項入組研究，其中61,961項招募研究和169,924項藥理學或生物學試驗正在蔓延。此外，聯合臨床影像研究資源計劃（U24s）由美國衛生署負責營運，該計劃的重點是最佳化臨床前和臨床環境中精準醫療的定量成像方法。我們支持 10 個涉及各種治療性介入和顯像模式的合作臨床試驗計劃。

北美地區預計將大幅成長

預計在預測期內，北美地區將在臨床試驗成像市場中佔據重要佔有率。因素包括醫療保健支出的增加、慢性病的流行以及老年人口的增加。例如，根據英聯邦組織的數據，2021年美國醫療保健系統佔GDP的17%，遠高於其他地區。此外，醫療保健領域的技術進步和政府資助的專家研究也有望進一步擴大市場規模。 Medpace 等市場領導的出現預計將進一步推動臨床試驗影像市場的發展。

主要市場參與者

IXICO 是一家總部位於英國的醫學影像服務供應商，致力於改善中樞神經系統臨床試驗的結果。透過其可遠端存取的 Trial Tacker 技術，該公司將於 2022 年 9 月建立並實施突破性的機器學習 AI資料分析，以幫助製藥公司提高藥物研究的投資收益，並降低臨床試驗期間風險的降低。 Navitas Life Sciences 是一家印度藥物開發和臨床研究公司，總部位於班加羅爾。該公司的主協議可提高腫瘤臨床試驗的成功率並以更低的成本更快地識別失敗。它也符合美國FDA 創造安全藥物的目標。 Resonance Health 是一家總部位於奧地利的醫療技術公司，專注於非侵入性醫學影像分析的開發和商業化。我們提供鐵過量、代謝性疾病、肝臟相關疾病、腦部疾病等檢測CRO服務和影像診斷服務。

市場主要發展

2023 年 3 月，Clario 為 CRO 推出了最先進的雲端基礎的影像檢視器工具。這使得 CRO 能夠透過直覺的基於網路的影像檢視器近乎即時地讀取高品質影像。 2023年1月，Cellac Imaging開發的混合伽瑪光學相機被引進美國臨床試驗程序。輻射用於對給予患者的放射性同位素進行成像。它還可用於骨骼、腎臟和感染疾病、淋巴結成像和定位前哨淋巴。 2022 年 11 月，VIDA Diagnostics 推出了其人工智慧支援平台的更新，稱為 VIDA Intelligence 2.0，以提高臨床試驗成像的效率。透過數位入職簡化臨床試驗參與者的註冊流程。

An imaging exam allows medical professionals to view what is happening inside the human body. These exams expose the body to various sources of energy, such as X-rays, sound waves, radioactive particles, or magnetic fields. The increasing investment in research projects to develop innovative medical solutions for long-lasting diseases such as cancer, chronic kidney disease, and others are major growth factors in the clinical trial imaging market. Moreover, the higher prevalence of this disease and demand for enhanced treatment solutions along with the emerging biotechnology companies due to rising healthcare expenditure are further contemplated to boost the clinical trial imaging market.

Increasing Biotechnological Companies

The increasing number of biotechnology companies with a focus on clinical trial imaging studies is expected to boost the clinical trial imaging market in the coming years. For instance, the Indian biotechnology industry crossed $80.12 billion in 2022 which is a 14% increase from 2021 as per the National Investment Promotion & Facilitation Agency, India. Moreover, around $1 billion was invested in the biotechnology R&D sector of India in 2022. The Australian biotechnology sector showed a 43% increase in 2022 from 2019 as per the AusBiotech Snapshot 2022. Moreover, the presence of leading biotechnology companies and emerging companies such as BioTelemetry, WCG Clinical, CRISPR Therapeutics, and 10x Genomics among others are further driving the clinical trial imaging market.

Increasing Cancer Cases

Imaging tests can be used to analyze cancers since they frequently exhibit a variety of structural, physiologic, and molecular changes as well as acquired biological abilities. Therefore, the rising cancer cases are contemplated to augment the clinical trial imaging market. For instance, one in six deaths, or around 10 million deaths, was due to cancer in 2020, making it the top cause of death globally as per the WHO. In low and lower-middle-income nations, cancer-causing infections including the human papillomavirus (HPV) and hepatitis are estimated to be the cause of 30% of cancer cases. The promise of novel targeted medicines with more focused action and reduced toxicity compared to standard chemotherapeutics is altering the management paradigm towards more tailored treatment and individualized care as the search for a cancer cure continues.

Growing Burden of Chronic Diseases

Chronic disease is a long-lasting condition that deteriorates a huge number of people on earth therefore, clinical trial imaging is crucial in earlier detection and treatment of disease as it ensures timely intervention. The rising cases of chronic diseases such as diabetes, kidney disease, cardiovascular diseases, and several others are expected to drive the clinical trial imaging market. For instance, More than one in seven adults in the United States, or around 37 million people, suffer from chronic kidney disease (CKD) as per the NIDDK. The primary cause of death in the world is cardiovascular disease (CVD). 32% of all fatalities worldwide in 2019 were predicted to have been caused by CVDs, killing 17.9 million individuals. Heart attack and stroke caused 85% of these fatalities according to the WHO.

Increasing Research Projects in the Field

The rising research projects including imaging clinical trials are another major growth driver in the clinical trial imaging market. For instance, the US National Library of Medicine reported that as of April 2022, there were 410,319 registered research spread throughout all 50 US states and 220 international locations, including 61,961 recruitment studies and 169,924 pharmacological or biological trials. Moreover, the Co-Clinical Imaging Research Resources Program (U24s) is run by the US Department of Health to focus on the optimization of quantitative imaging methods for precision medicine in preclinical and clinical settings. It supports ten co-clinical trial projects spanning a diverse range of therapeutic interventions, and imaging modalities.

North America is Expected to Grow Significantly

The North American region is projected to hold a significant share of the clinical trial imaging market during the forecasted period. Various factors attributed to such a share are increasing healthcare expenditure, the prevalence of chronic diseases, and the growing older population. For instance, the healthcare system in the US contributed 17% of GDP in 2021 which is way higher than other regions as per the Common Wealth Organization. Additionally, technological advancements and government-backed research in healthcare by experts are further expected to propel the market size. The presence of market leaders such as Medpace is further anticipated to boost the clinical trial imaging market.

Major Market Players

IXICO is a UK-based medical imaging services provider to enhance the outcomes of CNS trials. Through its remote access Trial Tacker Technology, the company created and implemented a ground-breaking machine learning AI data analytics in September 2022 to increase the pharmaceutical clients' return on investment in drug research and lower risk during clinical trials.
Navitas Life Sciences is an Indian drug development and clinical research company based out of Bengaluru. Master Protocol offered by the company increases the success rate and recognizes failure faster and at a lower cost in oncology clinical trials. It is also consistent with the US FDA's goal of helping and making safe drugs.
Resonance Health is an Austalia-based medical technology company with a focus on the development and commercialization of non-invasive medical imaging analysis. It provides laboratory CRO services and imaging services for iron overload disorders, metabolic disorders, liver-related disorders, and brain diseases.

Key Market Developments

In March 2023, a state-of-the-art cloud-based image viewer tool was introduced by Clario for CROs to use to view the images of their clinical trials. It enables CROs to read quality images in near real-time through an intuitive web-based imaging viewer.
In January 2023, a hybrid gamma optical camera developed by Serac Imaging was introduced in clinical trial procedures in the US. It uses radiation to image radioisotopes which are administered to the patients. It also helps in bone, renal, and infection imaging, lymphatic imaging, and sentinel lymph localization.
In November 2022, VIDA Diagnostics launched an updated artificial intelligence-enabled platform named VIDA Intelligence 2.0 to enhance clinical trial imaging efficiencies. It simplifies the participant's enrolment process for clinical trials through digital onboarding.

Segmentation

By Service

Clinical Trial Design & Consultation Services
Reading & Analytical Services
Operational Imaging Services
System & Technology Support Services
Project & Data Management

By Application

NASH
CKD
Diabetes
Cardiovascular Diseases
Musculoskeletal
Oncology
Gastroenterology
Pediatrics
Others

By End-Use

Biotechnology & Pharmaceutical companies
Medical Devices Manufacturers
Academic & Government Research Institutes
Contract Research Organizations (CROs)
Others

By Geography

North America
United States
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
United Kingdom
Germany
France
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Israel
Others
Asia Pacific
Japan
China
India
South Korea
Indonesia
Thailand
Others

1. INTRODUCTION

1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

2.1. Research Data
2.2. Assumptions

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers
4.2. Market Restraints
4.3. Porter's Five Force Analysis
- 4.3.1. Bargaining Power of Suppliers
- 4.3.2. Bargaining Power of Buyers
- 4.3.3. Threat of New Entrants
- 4.3.4. Threat of Substitutes
- 4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis

5. CLINICAL TRIAL IMAGING MARKET, BY SERVICE

5.1. Introduction
5.2. Clinical Trial Design & Consultation Services
5.3. Reading & Analytical Services
5.4. Operational Imaging Services
5.5. System & Technology Support Services
5.6. Project & Data Management

6. CLINICAL TRIAL IMAGING MARKET, BY APPLICATION

6.1. Introduction
6.2. NASH
6.3. CKD
6.4. Diabetes
6.5. Cardiovascular Diseases
6.6. Musculoskeletal
6.7. Oncology
6.8. Gastroenterology
6.9. Pediatrics
6.10. Others

7. CLINICAL TRIAL IMAGING MARKET, BY END-USE

7.1. Biotechnology & Pharmaceutical companies
7.2. Medical Devices Manufacturers
7.3. Academic & Government Research Institutes
7.4. Contract Research Organizations (CROs)
7.5. Others

8. CLINICAL TRIAL IMAGING MARKET, BY GEOGRAPHY

8.1. Introduction
8.2. North America
- 8.2.1. United States
- 8.2.2. Canada
- 8.2.3. Mexico
8.3. South America
- 8.3.1. Brazil
- 8.3.2. Argentina
- 8.3.3. Others
8.4. Europe
- 8.4.1. United Kingdom
- 8.4.2. Germany
- 8.4.3. France
- 8.4.4. Spain
- 8.4.5. Others
8.5. The Middle East and Africa
- 8.5.1. Saudi Arabia
- 8.5.2. UAE
- 8.5.3. Israel
- 8.5.4. Others
8.6. Asia Pacific
- 8.6.1. Japan
- 8.6.2. China
- 8.6.3. India
- 8.6.4. South Korea
- 8.6.5. Indonesia
- 8.6.6. Thailand
- 8.6.7. Others